Repurposing Strategies for Therapeutics

@article{Sleigh2012RepurposingSF,
  title={Repurposing Strategies for Therapeutics},
  author={S. Sleigh and C. L. Barton},
  journal={Pharmaceutical Medicine},
  year={2012},
  volume={24},
  pages={151-159}
}
  • S. Sleigh, C. L. Barton
  • Published 2012
  • Business
  • Pharmaceutical Medicine
  • Drug repurposing refers to the development of existing drugs for new indications. These drugs may have (i) failed to show efficacy in late stage clinical trials, without safety issues; (ii) stalled in development for commercial reasons; (iii) passed the point of patent expiry; or (iv) are being explored in new geographical markets. Over the past 5 years, pressure on the industry caused by the ‘innovation gap’ of rising development costs and stagnant product output have become major reasons for… CONTINUE READING
    104 Citations

    Figures and Tables from this paper

    Drug Repurposing: Far Beyond New Targets for Old Drugs
    • 149
    • PDF
    Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications
    • 18
    • Highly Influenced
    Drug repurposing: a promising tool to accelerate the drug discovery process.
    • 22
    Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature
    • 31
    Old wine in new bottles: Drug repurposing in oncology.
    • 11
    Drug repurposing and the prior art patents of competitors.
    • 14

    References

    SHOWING 1-10 OF 11 REFERENCES
    Matchmaking service links up researchers to wallflower drugs
    • 8
    Lessons from 60 years of pharmaceutical innovation
    • B. Munos
    • Medicine
    • Nature Reviews Drug Discovery
    • 2009
    • 934
    • Highly Influential
    • PDF
    Drug discovery dilemma and Cura quartet collaboration.
    • 9
    Why big pharma needs to learn the three 'R's
    • D. Bradley
    • Medicine
    • Nature Reviews Drug Discovery
    • 2005
    • 20
    Medicine. The NIH Roadmap.
    • 220
    Integration of indications discovery efforts at Pfizer
    • International Drug Discovery 2010;
    • 2010
    Why big pharma needs to learn the three Rs [ editorial analysis ]
    • Nat Rev Drug Discov
    • 2009
    Pharmaceutical product relaunch : preserving market share through line extension and new market entry strategies
    • Drug repurposing
    • 2007
    The NIH Roadmap
    • 247